IntegraGen announces that results from an analysis of miR-31-3p expression in tumor samples from patients enrolled in the NEW EPOC clinical trial have been published online in Oncotarget. The paper entitled “Association between miR-31- 3p expression and cetuximab efficacy in patients with KRAS wild-type metastatic colorectal cancer: a (…) »
Press releases // 28 September 2017
IntegraGen has announced its results for the first half of 2017.
IntegraGen today announced the CE-IVD marking and commercial launch of its miRpredX 31-3p test kit in the E.U., the first positive theranostic test for patients with metastatic colorectal cancer.
Click here for press release
Press releases // 28 April 2017
IntegraGen informs its shareholders and the financial community that its 2016 Annual Financial Report has been filed with the AMF.
Press releases // 21 April 2017
IntegraGen Announces 2016 Annual Results: Increase in operating revenues and significant improvement in operating income (+22%)
IntegraGen has announced its financial results for the year ending December 31, 2016. The financial statements were validated by the Company’s Board of Directors on April 20, 2017.
Press releases // 08 March 2017
Laboratoire CERBA signs licensing agreement with IntegraGen to commercialize miR-31-3p tumor expression test
IntegraGen SA and Laboratoire CERBA announced the signing of a licensing agreement allowing Laboratoire CERBA to develop and provide a test based on IntegraGen’s proprietary miR-31-3p biomarker to prescribing clinicians in France, Benelux, Middle East and Africa. Laboratoire CERBA will develop this test to complement its existing portfolio (…) »
Press releases // 03 February 2017
IntegraGen today announced that it has successfully completed a capital increase with cancellation of preferential subscription rights, reserved for a category of investors in the amount of € 3.7 million.
Objectives of Fundraising
The funds received will permit IntegraGen to accelerate its development by (…) »